ReviewCureus2017
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
Review in Cureus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Trial
- [Anabolic treatment in geriatric patients with osteoporosis].Zeitschrift fur Gerontologie und Geriatrie · 2026Review
- Abaloparatide-Zoledronate combination protects against 4-vinylcyclohexene diepoxide-induced postmenopausal osteoporosis in mice: an osteoanabolic-antiresorptive approach.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- G protein-coupled receptor signaling in osteogenic bone mesenchymal stem/stromal cells.Frontiers in cell and developmental biology · 2026Review
- Advances in Parathyroid Hormone-based medicines.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Review
- Distal Radius Fractures as a Call to Action: Reducing Subsequent Fragility Fracture Risk Through Early Osteoporosis Therapy.Geriatric orthopaedic surgery & rehabilitation · 2025Article
- Skeletal fluorosis: an uncommon cause, yet a rescue treatment?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy.Spine deformity · 2023Review
- Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1-34).JBMR plus · 2023Article
- A Vitronectin-Derived Peptide Restores Ovariectomy-Induced Bone Loss by Dual Regulation of Bone Remodeling.Tissue engineering and regenerative medicine · 2022Article
- An engineered dual function peptide to repair fractured bones.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Review
- Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?Current neuropharmacology · 2022Review
- Review
- Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice.Scientific reports · 2021Article
- Parathyroid Hormone 1 Receptor Signaling in Dental Mesenchymal Stem Cells: Basic and Clinical Implications.Frontiers in cell and developmental biology · 2021Review
- Diabetoporosis: Role of nitric oxide.EXCLI journal · 2021Review
- Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis.Nature reviews. Endocrinology · 2021Review
- Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020Review
- Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis. This paper reviews the profile and potential of abaloparatide in the treatment of postmenopausal osteoporosis. This paper is based on clinical trials and a PubMed search. Search terms used were "abaloparatide", "BA058", and "PTHrP". This review outlines the effects of this anabolic PTHR1 activator, which increases bone mineral density in patients at high risk for osteoporosis. The potential adverse effects of abaloparatide are also summarized. Abaloparatide has 41% homology to parathyroid hormone (PTH) (1-34) and 76% homology to parathyroid hormone-related protein (PTHrP) (1-34). The molecule was meticulously selected to retain stability and potent bone anabolic activity, and it has a limited effect on bone resorption (hence, a low calcium-mobilizing potential). Abaloparatide has shown promising results in a reduction of new onset vertebral (approximately 86% reduction) and nonvertebral fractures (approximately 43% reduction). In clinical trials to date, abaloparatide appears to have a good safety and tolerability profile with a significantly lower degree of hypercalcemia compared to that of teriparatide. Based on the clinical trials, the optimum dose of abaloparatide is 80 mcg subcutaneous once daily.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.